Novedades en el tratamiento del cáncer de próstata metastático hormono-independiente

Translated title of the contribution: Novel promising treatment options for metastatic androgen independent prostate cancer

Research output: Contribution to journalArticle

Abstract

Objective: Review the recent advances in the treatment of androgen independent prostate cancer (AIPC). Methods: Review recent abstracts and literature utilizing Medline/PubMed using key words: androgen independent/hormone refractory prostate cancer, novel treatment options, Phase II, III trials and meeting abstracts/presentations. Conclusion: Two pivotal trials SWOG (Southwest Oncology Group) study 9916 and Taxotere 327 have shown that survival can be improved in this population by administration of chemotherapy with docetaxel every three weeks intravenously. An overall survival of 19 months could be achieved with docetaxel/prednisone compared to16 months with mitoxantrone/ prednisone. Despite this, there is a need to improve on this survival benefit because the relapse free survival among responders is often short (6 months) and patients often would have progression of their cancer leading to death. Satraplatin, a novel platinum analogue had been found to provide an additional 1.5 week progression free survival benefit in this population in the second line setting. There is however, a need to develop less toxic drugs that would improve survival significantly.

Original languageSpanish
Pages (from-to)680-685
Number of pages6
JournalActas Urologicas Espanolas
Volume31
Issue number6
StatePublished - Jun 2007

Fingerprint

docetaxel
Androgens
Prostatic Neoplasms
Survival
Prednisone
Therapeutics
Mitoxantrone
Poisons
Platinum
PubMed
Population
Disease-Free Survival
Hormones
Recurrence
Drug Therapy
Pharmaceutical Preparations
Neoplasms

Keywords

  • Androgen independent/hormone refractory prostate cancer
  • Novel treatment options

ASJC Scopus subject areas

  • Urology

Cite this

Novedades en el tratamiento del cáncer de próstata metastático hormono-independiente. / Tan, Winston.

In: Actas Urologicas Espanolas, Vol. 31, No. 6, 06.2007, p. 680-685.

Research output: Contribution to journalArticle

@article{6024794c080249b9b498dd48acc34070,
title = "Novedades en el tratamiento del c{\'a}ncer de pr{\'o}stata metast{\'a}tico hormono-independiente",
abstract = "Objective: Review the recent advances in the treatment of androgen independent prostate cancer (AIPC). Methods: Review recent abstracts and literature utilizing Medline/PubMed using key words: androgen independent/hormone refractory prostate cancer, novel treatment options, Phase II, III trials and meeting abstracts/presentations. Conclusion: Two pivotal trials SWOG (Southwest Oncology Group) study 9916 and Taxotere 327 have shown that survival can be improved in this population by administration of chemotherapy with docetaxel every three weeks intravenously. An overall survival of 19 months could be achieved with docetaxel/prednisone compared to16 months with mitoxantrone/ prednisone. Despite this, there is a need to improve on this survival benefit because the relapse free survival among responders is often short (6 months) and patients often would have progression of their cancer leading to death. Satraplatin, a novel platinum analogue had been found to provide an additional 1.5 week progression free survival benefit in this population in the second line setting. There is however, a need to develop less toxic drugs that would improve survival significantly.",
keywords = "Androgen independent/hormone refractory prostate cancer, Novel treatment options",
author = "Winston Tan",
year = "2007",
month = "6",
language = "Spanish",
volume = "31",
pages = "680--685",
journal = "Actas Urologicas Espanolas",
issn = "0210-4806",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Novedades en el tratamiento del cáncer de próstata metastático hormono-independiente

AU - Tan, Winston

PY - 2007/6

Y1 - 2007/6

N2 - Objective: Review the recent advances in the treatment of androgen independent prostate cancer (AIPC). Methods: Review recent abstracts and literature utilizing Medline/PubMed using key words: androgen independent/hormone refractory prostate cancer, novel treatment options, Phase II, III trials and meeting abstracts/presentations. Conclusion: Two pivotal trials SWOG (Southwest Oncology Group) study 9916 and Taxotere 327 have shown that survival can be improved in this population by administration of chemotherapy with docetaxel every three weeks intravenously. An overall survival of 19 months could be achieved with docetaxel/prednisone compared to16 months with mitoxantrone/ prednisone. Despite this, there is a need to improve on this survival benefit because the relapse free survival among responders is often short (6 months) and patients often would have progression of their cancer leading to death. Satraplatin, a novel platinum analogue had been found to provide an additional 1.5 week progression free survival benefit in this population in the second line setting. There is however, a need to develop less toxic drugs that would improve survival significantly.

AB - Objective: Review the recent advances in the treatment of androgen independent prostate cancer (AIPC). Methods: Review recent abstracts and literature utilizing Medline/PubMed using key words: androgen independent/hormone refractory prostate cancer, novel treatment options, Phase II, III trials and meeting abstracts/presentations. Conclusion: Two pivotal trials SWOG (Southwest Oncology Group) study 9916 and Taxotere 327 have shown that survival can be improved in this population by administration of chemotherapy with docetaxel every three weeks intravenously. An overall survival of 19 months could be achieved with docetaxel/prednisone compared to16 months with mitoxantrone/ prednisone. Despite this, there is a need to improve on this survival benefit because the relapse free survival among responders is often short (6 months) and patients often would have progression of their cancer leading to death. Satraplatin, a novel platinum analogue had been found to provide an additional 1.5 week progression free survival benefit in this population in the second line setting. There is however, a need to develop less toxic drugs that would improve survival significantly.

KW - Androgen independent/hormone refractory prostate cancer

KW - Novel treatment options

UR - http://www.scopus.com/inward/record.url?scp=34548430641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548430641&partnerID=8YFLogxK

M3 - Article

C2 - 17896565

AN - SCOPUS:34548430641

VL - 31

SP - 680

EP - 685

JO - Actas Urologicas Espanolas

JF - Actas Urologicas Espanolas

SN - 0210-4806

IS - 6

ER -